| Geld/Brief | 13,81 $ / 13,79 $ |
| Spread | -0,14% |
| Schluss Vortag | 14,495 $ |
| Gehandelte Stücke | 1.300.125 |
| Tagesvolumen Vortag | 629.824,0 $ |
| Tagestief 13,57 $ Tageshoch 13,83 $ | |
| 52W-Tief 6,685 $ 52W-Hoch 15,415 $ | |
| Jahrestief 12,34 $ Jahreshoch 15,415 $ | |
| Umsatz in Mio. | 2.794 $ |
| Operatives Ergebnis (EBIT) in Mio. | 249,33 $ |
| Jahresüberschuss in Mio. | -73,88 $ |
| Umsatz je Aktie | 9,02 $ |
| Gewinn je Aktie | -0,38 $ |
| Gewinnrendite | +67,61% |
| Umsatzrendite | - |
| Return on Investment | -2,11% |
| Marktkapitalisierung in Mio. | 2.454 $ |
| KGV (Kurs/Gewinn) | -20,84 |
| KBV (Kurs/Buchwert) | - |
| KUV (Kurs/Umsatz) | 0,88 |
| Eigenkapitalrendite | - |
| Eigenkapitalquote | - |
| Handelsplatz | Letzter | Änderung | Vortag | Zeit | |
|---|---|---|---|---|---|
| Düsseldorf | 11,50 € | -3,36% | 11,90 € | 27.02.26 | |
| Frankfurt | 11,50 € | -4,17% | 12,00 € | 27.02.26 | |
| München | 12,466 € | +0,50% | 12,404 € | 27.02.26 | |
| Stuttgart | 11,50 € | -4,96% | 12,10 € | 27.02.26 | |
| L&S RT | 11,55 € | -2,94% | 11,90 € | 28.02.26 | |
| NYSE | 13,815 $ | -4,66% | 14,49 $ | 27.02.26 | |
| Nasdaq | 13,81 $ | -4,73% | 14,495 $ | 27.02.26 | |
| AMEX | 13,62 $ | -6,58% | 14,58 $ | 27.02.26 | |
| Tradegate | 12,70 € | +3,25% | 12,30 € | 27.02.26 | |
| Quotrix | 12,50 € | +1,63% | 12,30 € | 27.02.26 | |
| Gettex | 11,616 € | -5,27% | 12,262 € | 27.02.26 | |
| Datum | Kurs | Volumen |
|---|---|---|
| 27.02.26 | 13,83 | 1,51 M |
| 26.02.26 | 14,50 | 0,73 M |
| 25.02.26 | 14,57 | 0,82 M |
| 24.02.26 | 14,66 | 0,72 M |
| 23.02.26 | 14,42 | 0,65 M |
| Zeitraum | Kurs | % |
|---|---|---|
| 1 Woche | 14,50 $ | -4,76% |
| 1 Monat | 13,83 $ | -0,14% |
| 6 Monate | 9,36 $ | +47,54% |
| 1 Jahr | 8,38 $ | +64,80% |
| 5 Jahre | 5,44 $ | +153,86% |
| Marktkapitalisierung | 3,37 Mrd. € |
| Aktienanzahl | 306,54 Mio. |
| Streubesitz | 4,49% |
| Währung | EUR |
| Land | USA |
| Sektor | Gesundheit |
| Branche | Pharmazeutika |
| Aktientyp | Stammaktie |
| +5,59% | Vanguard Group Inc |
| +3,93% | TPG GP A, LLC |
| +3,86% | BlackRock Inc |
| +3,73% | Rubric Capital Management LP |
| +1,79% | Citadel Advisors Llc |
| +1,69% | Dimensional Fund Advisors, Inc. |
| +1,61% | Millennium Management LLC |
| +1,39% | Nantahala Capital Management, LLC |
| +1,25% | State Street Corp |
| +1,20% | Geode Capital Management, LLC |
| +1,19% | Neuberger Berman Group LLC |
| +1,10% | BlackBarn Capital Partners LP |
| +0,85% | Nuveen, LLC |
| +0,80% | Morgan Stanley - Brokerage Accounts |
| +0,71% | Goldman Sachs Group Inc |
| +0,61% | Qube Research & Technologies |
| +0,58% | Charles Schwab Investment Management Inc |
| +0,54% | Ameriprise Financial Inc |
| +0,54% | Arrowstreet Capital Limited Partnership |
| +0,51% | Northern Trust Corp |
| +62,07% | Weitere |
| +4,49% | Streubesitz |
CRL für IPX203
https://investors.amneal.com/news/press-releases/press-release-details/2023/Amneal-Receives-U.S.-FDA-Complete-Response-Letter-for-IPX203/default.aspx
Phase 3 RISE-PD Studie von IPX-203 (Parkinson) erreicht den primären Endpunkt
https://investors.amneal.com/news/press-releases/press-release-details/2021/Amneal-Announces-Positive-Topline-Results-from-Pivotal-Phase-3-RISE-PD-Clinical-Trial-of-IPX-203-in-Patients-with-Parkinsons-Disease-Who-Experience-Motor-Fluctuations/default.aspx
Amneal übernimmt Kashiv Bio
https://www.rttnews.com/3159700/amneal-pharma-announces-acquisition-of-kashiv-specialty-quick-facts.aspx